Evidence map›Paper›PMID 41591827›Full record

ArticleEmerging microbes & infections2026

Assessment of three antiviral compounds against Borealpox virus infection in a mouse model.

Jérémie Prévost, Nikesh Tailor, Angela Sloan, Kathleen Fulton, Sarah J Medina, Jonathan Audet, Geoff Soule, David Safronetz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jérémie PrévostSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Nikesh TailorSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Angela SloanSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Kathleen FultonSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Sarah J MedinaSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Jonathan AudetSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Geoff SouleSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
David SafronetzSpecial Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Borealpox virus (BRPV) is a zoonotic orthopoxvirus which was first documented in Alaska in 2015. Although most human infections are mild, a recent fatal case in an immunocompromised individual highlights the importance of studying this emerging pathogen. To date, less than 10 human cases of BRPV infection have been confirmed which limit the availability of clinical data on the effectiveness of antiviral therapy. Here, we examined the effectiveness of cidofovir, brincidofovir, and tecovirimat in cell culture and found all three were potent inhibitors of BRPV. In order to further study these modalities

Indexed as

Antiviral AgentsCytosineOrthopoxvirusPoxviridae InfectionsPyrimidinesAnimalsBenzamidesCidofovirDisease Models, AnimalFemaleHumansIsoindolesMiceMice, SCIDOrganophosphonatesPhthalimidesAntiviral AgentsBenzamidesbrincidofovirCidofovirCytosineIsoindolesOrganophosphonatesPhthalimidesPyrimidinestecovirimatBorealpoxbrincidofovircidofovirOrthopoxvirustecovirimatzoonotic disease

Identifiers

PMID41591827
PMCPMC12915423

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.